TITLE

UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF CIMZIA

PUB. DATE
May 2007
SOURCE
Worldwide Biotech;May2007, Vol. 19 Issue 5, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on the additional short-term clinical study initiated by UCB for the investigational drug product CIMZIA or certolizumab pegol. The additional study is designed to confirm the response of patients with moderate to severe active Crohn's disease to the drug. UCB decided to launch the additional clinical study to address the question raised by the U.S. Food and Drug Administration concerning the adequacy of one study design.
ACCESSION #
24795582

 

Related Articles

  • FDA Approves Cimzia for Crohn's Disease.  // Bioworld Week;4/28/2008, Vol. 16 Issue 17, p4 

    The article reports on the approval of UCB SA's Cimzia (certolizumab pegol), a PEGylated antitumor- necrosis-factor (TNF)-alpha antibody by the Food & Drug Administration (FDA) for Crohn's disease. It states that datum from Phase III pivotal studies presented patients with moderate to severe...

  • UCB initiates additional Cimzia study.  // European Pharmaceutical Executive;May2007, p12 

    The article reports on the decision of Belgium-based UCB Inc. (UI) to initiate an additional short-term clinical study of Cimzia or certolizumab pegol. This study will confirm the induction of clinical response in moderate to severe active Crohn's disease. UI will collaborate with the U.S. Food...

  • Recently Approved.  // Pharmaceutical Representative;May2007, Vol. 37 Issue 5, p14 

    The article presents the different drugs recently approved by the U.S. Food and Drug Administration. Humira of Abbott Laboratories Inc. has been denoted to reduce signs and symptoms of severely active Crohn's diseases in adults. UCB's Keppra has been authorized as adjunctive therapy in the...

  • COMPANY SPOTLIGHT - UCB.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p53 

    The article presents a corporate profile for biopharmaceutical company UCB. It is engaged in the research, development and commercialization of pharmaceutical and biotechnology products. It was granted approval from the U.S. Food and Drug Administration for its Crimzia intended for the treatment...

  • The Public: A Critical Initiative Partner. Getz, Ken // Applied Clinical Trials;Aug2005, Vol. 14 Issue 8, p50 

    Discusses the Critical Path Initiative of the U.S. Food and Drug Administration which acknowledges the challenges facing the clinical research enterprise. Collaboration among the scientific and drug development communities in order to improve the translation of biomedical information;...

  • Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. Dell'Utri, Chiara; Digesu, G.; Bhide, Alka; Khullar, Vik // International Urogynecology Journal;Oct2012, Vol. 23 Issue 10, p1337 

    Introduction and hypothesis: This is a systematic review of clinical data assessing the safety, efficacy and tolerability of fesoterodine in randomised control trials (RCTs) in the treatment of overactive bladder (OAB). Methods: We performed a MEDLINE literature search of articles published...

  • UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.  // Worldwide Biotech;Feb2007, Vol. 19 Issue 2, p2 

    The article reports that UCB got positive results for signs and symptoms from two Cimzia phase III studies in the treatment of rheumatoid arthritis. UCB has also received a complete response letter from the U.S. Food and Drug Administration requesting additional information and clarification on...

  • Policy Medicine Versus Policy Quakery: Economists Against the FDA. Klein, Daniel // Knowledge, Technology & Policy;Spring2000, Vol. 13 Issue 1, p92 

    Focuses on the policy of the government on pharmaceutical research in the United States. Role of the Food and Drug Administration in increasing the cost of pharmaceutical research; Restriction on drug benefit advertisement; List of drugs suffering delays.

  • Research analyzes the REMS landscape.  // Chain Drug Review;6/6/2011, Vol. 33 Issue 10, p17 

    The article reports on the release of the first comprehensive study by the Center for Healthcare Supply Chain Research, on the impact of the U.S. Food and Drug Administration's (FDA) Risk Evaluation and Mitigation Strategies (REMS).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics